Published in Am J Ophthalmol on August 26, 2009
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) (2013) 1.67
Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol (2012) 1.40
Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ (2012) 1.00
High Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis. Part Part Syst Charact (2014) 0.88
The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing. Clin Ophthalmol (2013) 0.88
The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model. Clin Ophthalmol (2012) 0.84
Angiogenin in age-related macular degeneration. Mol Vis (2011) 0.80
Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases. Biol Ther (2012) 0.77
Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys. PLoS One (2014) 0.76
Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol (2016) 0.76
Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis. Int J Ophthalmol (2015) 0.75
Quantifying the increasing use of anti-vascular endothelial growth factor therapy in ophthalmology. Mcgill J Med (2011) 0.75
Introducing Anti-Vascular Endothelial Growth Factor Therapies for AMD Did Not Raise Risk of Myocardial Infarction, Stroke, and Death. Ophthalmology (2016) 0.75
Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy. Invest New Drugs (2016) 0.75
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology (2010) 3.49
Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology (2009) 2.77
Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther (2008) 2.59
Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol (2006) 2.50
Evaluation of patients with scleritis for systemic disease. Ophthalmology (2004) 2.22
Retinal thickness analysis by race, gender, and age using Stratus OCT. Am J Ophthalmol (2009) 1.86
Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect (2013) 1.85
Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology (2005) 1.80
Recent trends in the management of rhegmatogenous retinal detachment. Surv Ophthalmol (2008) 1.78
Endothelial dystrophy, iris hypoplasia, congenital cataract, and stromal thinning (edict) syndrome maps to chromosome 15q22.1-q25.3. Am J Ophthalmol (2002) 1.56
Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. Retina (2010) 1.54
Comparison of time- and spectral-domain optical coherence tomography in management of diabetic macular edema. Invest Ophthalmol Vis Sci (2014) 1.45
New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence. Acta Ophthalmol Scand (2007) 1.40
Blood pressure control for diabetic retinopathy. Sao Paulo Med J (2015) 1.40
Punctate inner choroidopathy: a survey analysis of 77 persons. Ophthalmology (2007) 1.36
RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol (2010) 1.27
Progression of macular ischemia following intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging (2009) 1.25
Use of retinal procedures in medicare beneficiaries from 1997 to 2007. Arch Ophthalmol (2010) 1.14
Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology (2010) 1.13
A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology (2009) 1.13
Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology (2009) 1.12
Wide-field retinal imaging in the management of noninfectious posterior uveitis. Am J Ophthalmol (2012) 1.08
Hospitalized cardiovascular diseases in neovascular age-related macular degeneration. Arch Ophthalmol (2008) 1.07
Characterization of macular lesions in punctate inner choroidopathy with spectral domain optical coherence tomography. J Ophthalmic Inflamm Infect (2012) 1.07
Retinal optical coherence tomography manifestations of intraocular lymphoma. J Ophthalmic Inflamm Infect (2012) 1.01
Management of retained subretinal perfluorocarbon liquid. Ophthalmic Surg Lasers Imaging Retina (2013) 0.99
Mycophenolate mofetil and fundus autofluorescence in the management of recurrent punctate inner choroidopathy. Ocul Immunol Inflamm (2011) 0.96
Association of retinal sensitivity to integrity of photoreceptor inner/outer segment junction in patients with diabetic macular edema. Ophthalmology (2013) 0.96
Ultra-wide-field retinal imaging in the management of non-infectious retinal vasculitis. J Ophthalmic Inflamm Infect (2013) 0.95
New treatment options for noninfectious uveitis. Dev Ophthalmol (2012) 0.92
Myocardial infarction and cerebrovascular accident in patients with retinal vein occlusion. Arch Ophthalmol (2011) 0.89
Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. Am J Ophthalmol (2013) 0.89
Enterococcus casseliflavus endophthalmitis associated with a horse tail injury. Arch Ophthalmol (2009) 0.89
Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration. Am J Ophthalmol (2007) 0.88
Pneumatic retinopexy versus scleral buckle for repairing simple rhegmatogenous retinal detachments. Cochrane Database Syst Rev (2015) 0.87
Longitudinal spectral domain optical coherence tomography changes in eyes with intraocular lymphoma. J Ophthalmic Inflamm Infect (2013) 0.83
Macular sensitivity and fixation patterns in normal eyes and eyes with uveitis with and without macular edema. J Ophthalmic Inflamm Infect (2011) 0.83
Novel Therapies in Development for Diabetic Macular Edema. Curr Diab Rep (2015) 0.82
Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development. Biomed Res Int (2013) 0.82
Importance of proper diagnosis for management: multifocal choroiditis mimicking ocular histoplasmosis syndrome. J Ophthalmic Inflamm Infect (2011) 0.81
The role of biologic agents in the management of non-infectious uveitis. Expert Opin Biol Ther (2012) 0.81
Atypical Bartonella hensalae chorioretinitis in an immunocompromised patient. Ocul Immunol Inflamm (2008) 0.81
Hospitalized cardiovascular events in patients with diabetic macular edema. BMC Ophthalmol (2012) 0.81
Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy. Dev Ophthalmol (2015) 0.81
Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration. J Ocul Pharmacol Ther (2012) 0.80
Comparison of time domain and spectral domain optical coherence tomography in measurement of macular thickness in macular edema secondary to diabetic retinopathy and retinal vein occlusion. J Ophthalmol (2012) 0.80
Topical mecamylamine for diabetic macular edema. Am J Ophthalmol (2010) 0.79
Isolated endogenous Nocardia endophthalmitis after immunosuppression. J Ophthalmic Inflamm Infect (2012) 0.79
Anti-VEGF therapeutic approaches for diabetic macular edema. Int Ophthalmol Clin (2009) 0.78
Cystoid macular edema responds to intravitreal triamcinolone and rebounds after intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging (2009) 0.78
Fusion Proteins: Aflibercept (VEGF Trap-Eye). Dev Ophthalmol (2015) 0.78
A randomized, double-masked controlled clinical trial of Sandostatin long-acting release depot in patients with postsurgical cystoid macular edema. Retina (2010) 0.78
Aflibercept for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2016) 0.78
Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation. Expert Opin Drug Saf (2015) 0.78
Introduction to microperimetry and its use in analysis of geographic atrophy in age-related macular degeneration. Curr Opin Ophthalmol (2015) 0.78
Diagnostic and therapeutic challenges. Granulomatous panuveitis. Retina (2008) 0.77
Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema. Ocul Immunol Inflamm (2010) 0.77
Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate. BMC Pharmacol Toxicol (2013) 0.76
Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept. Retina (2015) 0.76
Progressive changes from idiopathic macular telangiectasia seen with spectral domain optical coherence tomography. Can J Ophthalmol (2010) 0.76
Ipilimumab-Associated Retinopathy. Ophthalmic Surg Lasers Imaging Retina (2015) 0.75
Diagnostic and therapeutic challenges. Retina (2011) 0.75
Retinal Vessel Caliber Measurement Using MultiColor and Infrared Confocal Scanning Laser Ophthalmoscopy Fundus Images. Int Ophthalmol Clin (2016) 0.75
Diagnostic and therapeutic challenges. Retina (2011) 0.75
Pharmacologic Vitreolysis in Vascular Diseases of the Retina. Ophthalmic Surg Lasers Imaging Retina (2016) 0.75
Diagnostic and therapeutic challenges. Retina (2013) 0.75
Sclerochoroidal calcifications imaged using enhanced depth imaging optical coherence tomography. Ocul Immunol Inflamm (2012) 0.75
Putting theories and results into practice: managing cases. Ophthalmology (2013) 0.75
ENDOGENOUS KLEBSIELLA PNEUMONIAE ENDOPHTHALMITIS IN NORTHERN CALIFORNIA. Retina (2017) 0.75
Resolution of macular edema in radiation retinopathy after intravenous diuresis. Retin Cases Brief Rep (2010) 0.75
FLUOCINOLONE ACETONIDE IMPLANT FOR VOGT-KOYANAGI-HARADA DISEASE: Three-Year Outcomes of Efficacy and Safety. Retina (2016) 0.75
Platelet-Derived Growth Factor Inhibitors: A Potential Therapeutic Approach for Ocular Neovascularization. Dev Ophthalmol (2015) 0.75
SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY EVALUATION OF RETINAL STRUCTURE IN PATIENTS WITH SUSACS SYNDROME. Retin Cases Brief Rep (2016) 0.75
Panuveitis in association with pseudotumor cerebri. J Child Neurol (2005) 0.75
The Role of Optical Coherence Tomography Angiography in the Management of Uveitis. Int Ophthalmol Clin (2016) 0.75
Persistent intermediate uveitis associated with latent manifestation of facial large B-cell non-Hodgkin lymphoma. Ocul Immunol Inflamm (2009) 0.75
Nodular sclerochoroidopathy simulating choroidal malignancy. Ophthalmic Surg Lasers Imaging (2010) 0.75
Diagnostic and therapeutic challenges. Acute onset panuveitis. Retina (2010) 0.75
Structural Characteristics of Retinal Layers Adjacent to Geographic Atrophy. Ophthalmic Surg Lasers Imaging Retina (2015) 0.75
Eight questions with Dr. Puliafito. Ophthalmic Surg Lasers Imaging Retina (2013) 0.75
Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel. Ophthalmic Surg Lasers Imaging Retina (2017) 0.75